Australia markets closed

Neuronetics, Inc. (STIM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.3700-0.1650 (-4.67%)
At close: 04:00PM EDT
3.3500 -0.02 (-0.59%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.5350
Open3.4900
Bid3.3600 x 500
Ask3.4400 x 100
Day's range3.2500 - 3.5362
52-week range1.0300 - 5.0700
Volume61,828
Avg. volume164,781
Market cap101.014M
Beta (5Y monthly)2.44
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The confere

  • GlobeNewswire

    New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

    Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in t

  • GlobeNewswire

    Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees. In accordance with NASDAQ Listing Rule